News for Anavex Life Sciences Corp. (AVXL)

The borrow rate for Anavex (AVXL) has seen a notable increase recently. The company's borrow rate has risen by 14.68%, marking an uptick of 0.76 percentage poin

PHILADELPHIA, June 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims c

Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice Pr

**media[630787]**

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAVXL.OQ - Anavex Life Sciences CorpQ2 2025 Anavex Life Sciences Corp Earnings CallMay 13, 2025

H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference NEW YORK, May 14, 2025 (GLO

Anavex Life Sciences (AVXL) to present at two major healthcare conferences in New York City. CEO Christopher U. Missling to showcase the company's advan

The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities.

Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (”œAnavex”

Anavex Life Sciences (AVXL) schedules its fiscal 2025 second-quarter earnings release for May 13, 2025. The company will host a conference call and webc

Anavex Life Sciences (AVXL) has successfully wrapped up participant enrollment for its Phase 2 clinical trial of ANAVEX3-71 aimed at treating schizophrenia. Thi

**media[611519]**

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (”œAnavex” or the ”œCompany”) ( AVXL), a clinical-stage biopharmaceutical compan

Anavex Life Sciences Corp. (AVXL) has bolstered its Scientific Advisory Board by welcoming Professor Dr. Audrey Gabelle, MD, PhD. Dr. Gabelle is renowned for he

**media[602841]**

Anavex Life Sciences (AVXL) presented significant findings at the 9th International Conference on Alzheimer's Disease in Abu Dhabi. The presentation foc

**media[600326]**

Anavex Life Sciences Corp. (AVXL) showcases promising long-term results for its Alzheimer's drug in the ATTENTION-AD trial. Analysts predict a significa

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral